Salivary Gland Cancer
Eribulin for Locally Advanced Salivary Gland Cancers (7674)
Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers
Investigator: Keith D. Eaton, MD; Conditions: Salivary Gland Cancer; Status: Recruiting; Study ID: NCT01613768
Join Us On